Novo Nordisk has released the findings of its REDEFINE 2 trial, which compared the new weight loss drug, CagriSema, in adults with type 2 diabetes and overweight or obesity. CagriSema consists of two drugs, cagrilintide and semaglutide, aimed at suppressing hunger and weight loss.
The researchers set out to find out how over-time variation in insulin resistance (IR) may influence the development of cardiovascular disease (CVD). Researchers studied data from a large Chinese health survey and used two key markers to measure IR: the triglyceride-glucose (TyG) index and the TyG-BMI index (which combines TyG with body mass index).
This cross-sectional study by Sato et al. investigates the impact of Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors on nocturnal polyuria in type 2 diabetic patients, in particular on a comparison between the short-acting inhibitor tofogliflozin and other SGLT2 inhibitors. The sample was 142 patients, divided into two groups: one that received SGLT2 inhibitors and one that received none.
The study explores the correlation between blood glucose level and early signs of a cardiac disease called aortic valve calcification (AVC) in middle-aged people. AVC is a disease in which calcium deposits in the aortic valve harden the valve, and it may eventually lead to aortic stenosis (AS). Without treatment, the disease is hazardous, as it affects the blood flow from the heart.
A research study looked at the impact of a 1-week low-carbohydrate diet on increasing insulin sensitivity and vascular function in type 1 diabetes.
